Six Months of Hydroxyurea Reduces Albuminuria in Patients with Sickle Cell Disease
Six Months of Hydroxyurea Reduces Albuminuria in Patients with Sickle Cell Disease
复制标题
DOI：
10.1681/asn.2014111126
复制
发表时间：
2016-06-01
影响因子：
13.6
通讯作者：
Audard, Vincent
中科院分区：
文献类型：
--
作者：
Bartolucci, Pablo;Habibi, Anoosha;Audard, Vincent
The earliest symptom of glomerular injury in patients with sickle cell disease (SCD) is microalbuminuria. The effect of hydroxyurea (HU) on urine albumin-to-creatinine ratio (ACR) is unclear and should be determined, because increasing numbers of patients with SCD take this drug to improve red blood cell function. In this cohort study of 58 SS-homozygous adults with SCD who initiated HU therapy, we evaluated ACR changes and relationships of these changes with demographic, clinical, and biologic parameters at HU initiation (baseline) and 6 months later (follow-up). Between baseline and follow-up, ACR declined significantly for the entire population (3.0-1.7 mg/mmol; P
